SCHEMBL6900365

SCHEMBL6900365

Nc1ncnc2c1ncn2[C@H]1O[C@H](COc2ccccn2)[C@H](O)[C@H]1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 5/20 0.70
SMN1; SMN2 Q16637 3/20 0.66
ADORA3 P0DMS8 2/20 0.66
ADORA2A P29274 2/20 0.66
ADORA2B P29275 2/20 0.66
DPP4 P27487 1/20 0.66
MEN1 O00255 1/20 0.66
SLC28A1 O00337 1/20 0.66
MAP3K7 O43318 1/20 0.66
SLC28A2 O43868 1/20 0.66
GAPDH P04406 1/20 0.66
MAPK1 P28482 1/20 0.66
STAT6 P42226 1/20 0.66
PI4KA P42356 1/20 0.66
KMT2A Q03164 1/20 0.66
PI4K2B Q8TCG2 1/20 0.66
DOT1L Q8TEK3 1/20 0.66
SLC29A1 Q99808 1/20 0.66
PI4K2A Q9BTU6 1/20 0.66
SLC28A3 Q9HAS3 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6905464 0.88 ADORA1 (0.72) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL1434032 0.88 ADORA1 (0.72) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL9491623 0.86 ADORA1 (0.67) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL9341019 0.84 ADORA1 (0.68) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8610899 0.84 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL8610903 0.84 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL31484253 0.84 ADORA1 (0.82) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL10997946 0.84 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL12963362 0.84 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL481524 0.84 ADORA1 (0.76) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1482977-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2004-12-08 EP disclosed
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed
WO-2003074083-A1 COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS PFIZER INC. (US) 2003-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP ADORA1 858/4885SMN1; SMN2 1993/4885ADORA3 743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.